Novo Nordisk and GoodRx announced a partnership this week to sell products Ozempic and Wegovy at half their normal cost to ...

Novo Nordisk lowers Ozempic cost to $499 per month for uninsured U.S. patients, expanding access through NovoCare and 70,000 ...

The U.S. Food and Drug Administration approved the obesity drug Wegovy for people with the chronic liver disease known as ...

Viking Therapeutics (VKTX) stock drops as its oral obesity drug VK2735 trails Novo's (NVO) oral Wegovy and Lilly's (LLY) ...

GoodRx reports that insurance formularies are shrinking, leading to fewer covered medications and increased restrictions on ...

Health Canada approved Ozempic for type 2 diabetes patients with chronic kidney disease after positive FLOW trial results.

Novo Nordisk is slashing the price of its blockbuster diabetes drug Ozempic for U.S. patients who self-pay or are uninsured.

Although the FDA has since removed these drugs from its shortage list, stakeholders say compounded drugs continue to be sold.

Wegovy is now positioned as the first and only GLP-1 treatment.

Saxenda falls outside Medicare drug plan coverage because Medicare does not cover GLP-1 agonists when doctors prescribe them specifically for weight management.

Recent federal and state developments have shifted the ground under medispas. The US Food and Drug Administration (FDA) ...

Viking Therapeutics stock plunges 37% as trial data sparks concerns over dropout rates and side effects despite weight loss ...